<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">37674565</PMID><DateRevised><Year>2023</Year><Month>09</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2772-7076</ISSN><JournalIssue CitedMedium="Internet"><Volume>8</Volume><PubDate><Year>2023</Year><Month>Sep</Month></PubDate></JournalIssue><Title>IJID regions</Title><ISOAbbreviation>IJID Reg</ISOAbbreviation></Journal><ArticleTitle>Burden, causation, and particularities of Long COVID in African populations: A rapid systematic review.</ArticleTitle><Pagination><StartPage>137</StartPage><EndPage>144</EndPage><MedlinePgn>137-144</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.ijregi.2023.08.004</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To determine the prevalence of long COVID, its most common symptoms, comorbidities, and pathophysiological mechanisms in African populations.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">A systematic review of long COVID in African populations was conducted. The random effects model was used to calculate the pooled prevalence rates (95% CI). A narrative synthesis was also performed.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">We included 14 studies from seven African countries, totaling 6030 previously SARS-CoV-2 infected participants and 2954 long COVID patients. Long COVID had a pooled prevalence of 41% (26-56%). Fatigue, dyspnea, and confusion or lack of concentration were the most common symptoms, with prevalence rates (95% CI) of 41% (26-56%), 25% (12-38%), and 40% (12-68%), respectively. Long COVID was mainly associated with advanced age, being female, more than three long COVID symptoms in the acute phase, initial fatigue and dyspnea, COVID-19 severity, pre-existing obesity, hypertension, diabetes mellitus, and the presence of any chronic illness (<i>P</i> &#x2264;0.05). High microclot and platelet-poor plasma viscosity explained the pathophysiology of long COVID.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="UNASSIGNED">Long COVID prevalence in Africa was comparable to the global prevalence. The most common symptoms were higher in Africa. Comorbidities associated with long COVID may lead to additional complications in African populations due to hypercoagulation and thrombosis.Systematic review registration: PROSPERO CRD42023430024.</AbstractText><CopyrightInformation>&#xa9; 2023 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nyasulu</LastName><ForeName>Peter S</ForeName><Initials>PS</Initials><AffiliationInfo><Affiliation>Division of Epidemiology &amp; Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Epidemiology &amp; Biostatistics, School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Parktown, Johannesburg, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tamuzi</LastName><ForeName>Jacques L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>Division of Epidemiology &amp; Biostatistics, Department of Global Health, Faculty of Medicine and Health Sciences, Stellenbosch University, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Erasmus</LastName><ForeName>Rajiv T</ForeName><Initials>RT</Initials><AffiliationInfo><Affiliation>Division of Chemical Pathology, Department of Pathology, Faculty of Medicine and Health Sciences, Stellenbosch University &amp; NHLS Tygerberg Hospital, Cape Town, South Africa.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>08</Month><Day>09</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>IJID Reg</MedlineTA><NlmUniqueID>9918418183106676</NlmUniqueID><ISSNLinking>2772-7076</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">African populations</Keyword><Keyword MajorTopicYN="N">Comorbidities</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Pathophysiology</Keyword><Keyword MajorTopicYN="N">Prevalence</Keyword><Keyword MajorTopicYN="N">Symptoms</Keyword></KeywordList><CoiStatement>The authors have no competing interests to declare.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>5</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>8</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>8</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>9</Month><Day>7</Day><Hour>4</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2023</Year><Month>8</Month><Day>9</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37674565</ArticleId><ArticleId IdType="pmc">PMC10477483</ArticleId><ArticleId IdType="doi">10.1016/j.ijregi.2023.08.004</ArticleId><ArticleId IdType="pii">S2772-7076(23)00080-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Aly MAEG, Saber HG. Long COVID and chronic fatigue syndrome: a survey of elderly female survivors in Egypt. Int J Clin Pract. 2021;75:e14886. doi: 10.1111/ijcp.14886.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijcp.14886</ArticleId><ArticleId IdType="pmc">PMC8646426</ArticleId><ArticleId IdType="pubmed">34537995</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis HE, Assaf GS, McCorkell L, Wei H, Low RJ, Re'em Y, et al. Characterizing long COVID in an international cohort: 7 months of symptoms and their impact. EClinicalmedicine. 2021;38 doi: 10.1016/j.eclinm.2021.101019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101019</ArticleId><ArticleId IdType="pmc">PMC8280690</ArticleId><ArticleId IdType="pubmed">34308300</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre CH, Murray B, Varsavsky T, Graham MS, Penfold RS, Bowyer RC, et al. Attributes and predictors of long COVID. Nat Med. 2021;27:626&#x2013;631. doi: 10.1038/s41591-021-01292-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01292-y</ArticleId><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Centers for Disease Control and Prevention. Long COVID or post-COVID conditions. Available on: https://www.cdc.gov/coronavirus/2019-ncov/long-term-effects/index.html. [accessed 29 May 2023].</Citation></Reference><Reference><Citation>Akbarialiabad H, Taghrir MH, Abdollahi A, Ghahramani N, Kumar M, Paydar S, et al. Long COVID, a comprehensive systematic scoping review. Infection. 2021;49:1163&#x2013;1186. doi: 10.1007/s15010-021-01666-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s15010-021-01666-x</ArticleId><ArticleId IdType="pmc">PMC8317481</ArticleId><ArticleId IdType="pubmed">34319569</ArticleId></ArticleIdList></Reference><Reference><Citation>Baig AM. Deleterious outcomes in Long-Hauler COVID-19: the effects of SARS-CoV-2 on the CNS in chronic COVID syndrome. ACS Chem Neurosci. 2020;11:4017&#x2013;4020. doi: 10.1021/acschemneuro.0c00725.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acschemneuro.0c00725</ArticleId><ArticleId IdType="pubmed">33275404</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. COVID-19 weekly epidemiological update. Available on: https://www.who.int/publications/m/item/weekly-epidemiological-update-on-covid-19-18. 2023. [accessed 30 May 2023].</Citation></Reference><Reference><Citation>Dryden M, Mudara C, Vika C, Blumberg L, Mayet N, Cohen C, et al. Post-COVID-19 condition 3 months after hospitalisation with SARS-CoV-2 in South Africa: a prospective cohort study. Lancet Glob Health. 2022;10:e1247&#x2013;e1256. doi: 10.1016/S2214-109X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2214-109X</ArticleId><ArticleId IdType="pmc">PMC9363040</ArticleId><ArticleId IdType="pubmed">35961348</ArticleId></ArticleIdList></Reference><Reference><Citation>Peluso MJ, Spinelli MA, Deveau TM, Forman CA, Munter SE, Mathur S, et al. Postacute sequelae and adaptive immune responses in people with HIV recovering from SARS-COV-2 infection. AIDS (Lond Engl) 2022;36:F7&#x2013;F16. doi: 10.1097/QAD.0000000000003338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/QAD.0000000000003338</ArticleId><ArticleId IdType="pmc">PMC9444925</ArticleId><ArticleId IdType="pubmed">35866847</ArticleId></ArticleIdList></Reference><Reference><Citation>Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. PLoS Med. 2021;18 doi: 10.1371/journal.pmed.1003583.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pmed.1003583</ArticleId><ArticleId IdType="pmc">PMC8007028</ArticleId><ArticleId IdType="pubmed">33780438</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Vlok M, Venter C, Bezuidenhout JA, Laubscher GJ, Steenkamp J, et al. Persistent clotting protein pathology in long COVID/post-acute sequelae of COVID-19 (PASC) is accompanied by increased levels of antiplasmin. Cardiovasc Diabetol. 2021;20:172. doi: 10.1186/s12933-021-01359-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-021-01359-7</ArticleId><ArticleId IdType="pmc">PMC8381139</ArticleId><ArticleId IdType="pubmed">34425843</ArticleId></ArticleIdList></Reference><Reference><Citation>Kruger A, Vlok M, Turner S, Venter C, Laubscher GJ, Kell DB, et al. Proteomics of fibrin amyloid microclots in long COVID/post-acute sequelae of COVID-19 (PASC) shows many entrapped pro-inflammatory molecules that may also contribute to a failed fibrinolytic system. Cardiovasc Diabetol. 2022;21:190. doi: 10.1186/s12933-022-01623-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01623-4</ArticleId><ArticleId IdType="pmc">PMC9491257</ArticleId><ArticleId IdType="pubmed">36131342</ArticleId></ArticleIdList></Reference><Reference><Citation>El Otmani H, Nabili S, Berrada M, Bellakhdar S, El Moutawakil B, Abdoh Rafai M. Prevalence, characteristics and risk factors in a Moroccan cohort of Long-Covid-19. Neurol Sci. 2022;43:5175&#x2013;5180. doi: 10.1007/s10072-022-06138-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10072-022-06138-0</ArticleId><ArticleId IdType="pmc">PMC9132567</ArticleId><ArticleId IdType="pubmed">35614173</ArticleId></ArticleIdList></Reference><Reference><Citation>Walker M, Federico EM, Kell DB, Dupont C, Proal A, Pretorius E. Detection and characterization of fibrin/amyloid microclots in patients with post-acute sequelae of Covid-19. Circulation. 2022;146:A15637. doi: 10.1161/circ.146.suppl_1.15637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/circ.146.suppl_1.15637</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner S, Naidoo CA, Usher TJ, Kruger A, Venter C, Laubscher GJ, et al. Increased levels of inflammatory and endothelial biomarkers in blood of long COVID patients point to thrombotic endothelialitis. Semin Thromb Hemost. 2023 doi: 10.1055/s-0043-1769014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0043-1769014</ArticleId><ArticleId IdType="pubmed">37207671</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogoina D, James HI, Ogoinja SZ. Post-discharge symptoms among hospitalized COVID-19 patients in Nigeria: a single-center study. Am J Trop Med Hyg. 2021;105:731&#x2013;736. doi: 10.4269/ajtmh.21-0509.</Citation><ArticleIdList><ArticleId IdType="doi">10.4269/ajtmh.21-0509</ArticleId><ArticleId IdType="pmc">PMC8592373</ArticleId><ArticleId IdType="pubmed">34270448</ArticleId></ArticleIdList></Reference><Reference><Citation>Osikomaiya B, Erinoso O, Wright KO, Odusola AO, Thomas B, Adeyemi O, et al. &#x2018;Long COVID&#x2019;: persistent COVID-19 symptoms in survivors managed in Lagos State, Nigeria. BMC Infect Dis. 2021;21:304. doi: 10.1186/s12879-020-05716-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-020-05716-x</ArticleId><ArticleId IdType="pmc">PMC7993075</ArticleId><ArticleId IdType="pubmed">33765941</ArticleId></ArticleIdList></Reference><Reference><Citation>Pretorius E, Venter C, Laubscher GJ, Kotze MJ, Oladejo SO, Watson LR, et al. Prevalence of symptoms, comorbidities, fibrin amyloid microclots and platelet pathology in individuals with long COVID/post-acute sequelae of COVID-19 (PASC) Cardiovasc Diabetol. 2022;21:148. doi: 10.1186/s12933-022-01579-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12933-022-01579-5</ArticleId><ArticleId IdType="pmc">PMC9356426</ArticleId><ArticleId IdType="pubmed">35933347</ArticleId></ArticleIdList></Reference><Reference><Citation>Zulu JE, Banda D, Hines JZ, Luchembe M, Sivile S, Siwingwa M, et al. Two-month follow-up of persons with SARS-CoV-2 infection-Zambia, September 2020: a cohort study. Pan Afr Med J. 2022;41:26. doi: 10.11604/pamj.2022.41.26.30721.</Citation><ArticleIdList><ArticleId IdType="doi">10.11604/pamj.2022.41.26.30721</ArticleId><ArticleId IdType="pmc">PMC8895565</ArticleId><ArticleId IdType="pubmed">35291364</ArticleId></ArticleIdList></Reference><Reference><Citation>Mendelsohn AS, Nath N, De S&#xe1; A, Von Pressentin KB. Two months follow-up of patients with non-critical COVID-19 in Cape Town, South Africa. S Afr Fam Pract (2004) 2022;64:e1&#x2013;e6. doi: 10.4102/safp.v64i1.5429.</Citation><ArticleIdList><ArticleId IdType="doi">10.4102/safp.v64i1.5429</ArticleId><ArticleId IdType="pmc">PMC8905322</ArticleId><ArticleId IdType="pubmed">35144461</ArticleId></ArticleIdList></Reference><Reference><Citation>Galal I, Hussein AA, Amin MT, Saad MM, Zayan HE, Abdelsayed MZ, et al. Determinants of persistent post-COVID-19 symptoms: value of a novel COVID-19 symptom score. Egypt J Bronchol. 2021;15:1&#x2013;8. doi: 10.1186/s43168-020-00049-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s43168-020-00049-4</ArticleId></ArticleIdList></Reference><Reference><Citation>Crankson S, Pokhrel S, Anokye NK. Determinants of COVID-19-related length of hospital stays and long COVID in Ghana: a cross-sectional analysis. Int J Environ Res Public Health. 2022;19 doi: 10.3390/ijerph19010527.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijerph19010527</ArticleId><ArticleId IdType="pmc">PMC8744866</ArticleId><ArticleId IdType="pubmed">35010786</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazzitelli M, Trunfio M, Sasset L, Leoni D, Castelli E, Lo Menzo S, et al. Factors associated with severe COVID-19 and post-acute COVID-19 syndrome in a cohort of people living with HIV on antiretroviral treatment and with undetectable HIV RNA. Viruses. 2022;14:493. doi: 10.3390/v14030493.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v14030493</ArticleId><ArticleId IdType="pmc">PMC8954437</ArticleId><ArticleId IdType="pubmed">35336900</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C, Haupert SR, Zimmermann L, Shi X, Fritsche LG, Mukherjee B. Global prevalence of post-coronavirus disease 2019 (COVID-19) condition or long COVID: a meta-analysis and systematic review. J Infect Dis. 2022;226:1593&#x2013;1607. doi: 10.1093/infdis/jiac136.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiac136</ArticleId><ArticleId IdType="pmc">PMC9047189</ArticleId><ArticleId IdType="pubmed">35429399</ArticleId></ArticleIdList></Reference><Reference><Citation>Jassat W, Blumberg L, Cohen C, Potgieter S, Black J, Parker A, et al. Undiagnosed comorbidities among individuals hospitalised with COVID-19 in South African public hospitals. S Afr Med J. 2022;112:747&#x2013;752. doi: 10.7196/SAMJ.2022.v112i9.16417.</Citation><ArticleIdList><ArticleId IdType="doi">10.7196/SAMJ.2022.v112i9.16417</ArticleId><ArticleId IdType="pubmed">36214039</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328:1604&#x2013;1615. doi: 10.1001/jama.2022.18931.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2022.18931</ArticleId><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Aly Z, Bowe B, Xie Y. Long COVID after breakthrough SARS-CoV-2 infection. Nat Med. 2022;28:1461&#x2013;1467. doi: 10.1038/s41591-022-01840-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-022-01840-0</ArticleId><ArticleId IdType="pmc">PMC9307472</ArticleId><ArticleId IdType="pubmed">35614233</ArticleId></ArticleIdList></Reference><Reference><Citation>Neville TH, Hays RD, Tseng CH, Gonzalez CA, Chen L, Hong A, et al. Survival after severe COVID-19: long-term outcomes of patients admitted to an intensive care unit. J Intensive Care Med. 2022;37:1019&#x2013;1028. doi: 10.1177/08850666221092687.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/08850666221092687</ArticleId><ArticleId IdType="pmc">PMC8990100</ArticleId><ArticleId IdType="pubmed">35382627</ArticleId></ArticleIdList></Reference><Reference><Citation>Nishiga M, Wang DW, Han Y, Lewis DB, Wu JC. COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives. Nat Rev Cardiol. 2020;17:543&#x2013;558. doi: 10.1038/s41569-020-0413-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-020-0413-9</ArticleId><ArticleId IdType="pmc">PMC7370876</ArticleId><ArticleId IdType="pubmed">32690910</ArticleId></ArticleIdList></Reference><Reference><Citation>Rahaghi FN, Pistenmaa CL. Hypercoagulation in COPD: the clot thickens. ERJ Open Res. 2021;7:00534&#x2013;02021. doi: 10.1183/23120541.00534-2021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00534-2021</ArticleId><ArticleId IdType="pmc">PMC8558549</ArticleId><ArticleId IdType="pubmed">34729371</ArticleId></ArticleIdList></Reference><Reference><Citation>Notarte KI, Catahay JA, Velasco JV, Pastrana A, Ver AT, Pangilinan FC, et al. Impact of COVID-19 vaccination on the risk of developing long-COVID and on existing long-COVID symptoms: a systematic review. EClinicalmedicine. 2022;53 doi: 10.1016/j.eclinm.2022.101624.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101624</ArticleId><ArticleId IdType="pmc">PMC9417563</ArticleId><ArticleId IdType="pubmed">36051247</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>